2003 archivos - Página 2 de 2 - Histopat laboratoris

HER-2/neu status in breast carcinoma: overexpression versus amplification

Verdú M^1,Colomer A^2,Román R^2,Erill N^2,Moreno A^1,Cordón-Cardo C^1,2,Puig X^1,2.

¹HISTOPAT Laboratoris & ²BIOPAT. Grup Assistència. Barcelona (Spain).

HER-2/neu is a critical marker in assessing the molecular profile of breast cancer, as it represents a target for therapeutic intervention. HER-2/neu gene amplification has been reported to be associated with treatment response. Immunohistochemistry (IHC) to detect HER-2/neu protein overexpression was initially recommended as the technique of choice to assign patients to Herceptin clinical treatment. However, different studies have shown […]

Alberto 2003-02-23T17:27:24+00:00

Molecular evaluation of TP53 status in human colorectal and urinary bladder cancer: phenotype versus genotype analysis

Erill N¹, Colomer A¹, Verdú M², Román R¹, Vidal A², Condom E², Banús JM³, Cordón-Cardo C^1,2, Puig X^1,2.

¹BIOPAT. Grup Assistència, ²HISTOPAT Laboratoris & ³ICUN. Institut Català d’Urologia i Nefrologia. Barcelona (Spain).

Mutations of the TP53 tumor suppressor gene and nuclear accumulation of abnormal p53 proteins are common in colon and bladder cancer, and have been associated with clinical aggressiveness and poor response to specific therapies. However, there is no general agreement regarding the optimal technical approach to define the TP53 status […]

Alberto 2003-02-23T16:49:37+00:00

Previous 1 2